Laminin Mediator for Retinal Cell Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic methods for retinal pigment epithelial and nerve disorders, such as age-related macular degeneration and retinitis pigmentosa, lack effective solutions for promoting cell adhesion and regeneration, limiting their ability to address diminished visual acuity and nervous function.
Innovation Solution
The use of specific laminins, including laminin 511 and laminin 521, and their fragments, such as the laminin 511-E8 fragment, which promote cell adhesion and are administered with a ROCK inhibitor like Y-27632, to enhance the therapeutic or prophylactic treatment of retinal pigment epithelial and nerve cells, facilitating cell transplantation and regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic methods are used for retinal pigment epithelial and nerve disorders, then treatment is provided, but cell adhesion and regeneration are not effectively promoted
Solution Approach 1:
The patent introduces laminin as an intermediary substance that mediates between the transplant environment and retinal pigment epithelial/nerve cells. Laminin serves as a biological mediator that specifically promotes cell adhesion and survival without requiring complex manufacturing processes, thus resolving the contradiction between therapeutic effectiveness and ease of implementation.
Solution Approach 2:
The patent changes the biochemical parameters of the transplant environment by introducing specific laminin isoforms (such as laminin-511 and laminin-521). This parameter change in the extracellular matrix composition directly enhances cell adhesion and regeneration capabilities, improving therapeutic effectiveness without complicating the overall treatment protocol.
2Reliability
If cell transplantation is performed without adhesion promoters, then transplantation procedure is simple, but cell engraftment and survival are limited
Solution Approach 1:
Laminin acts as a biological intermediary that bridges the gap between transplanted cells and the host tissue environment. This single mediator substance simplifies the overall system while dramatically improving cell engraftment rates, avoiding the need for complex multi-component devices or procedures.
Solution Approach 2:
The patent utilizes laminin's inherent biological properties to enable self-service functionality in the transplant system. Laminin naturally promotes cell adhesion, survival, and integration without requiring external activation or complex control mechanisms, thus improving reliability while maintaining system simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly improves cell adhesion and engraftment of transplanted cells onto subretinal tissue, offering a novel therapeutic option for retinal and nerve disorders by promoting regenerative medicine through enhanced cell growth and tissue repair.
Implementation Method 1
the inventors' discovery that specific laminins promote adhesion of especially retinal pigment epithelial and/or nerve cells
Data Source
AI summary
The present invention provides a technique for treating retinal epithelium and/or nerves. More specifically, the present invention is an agent for the treatment or prevention of retinal disease or the like and/or a disease, disorder, or ophthalmological state of the nerves, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with retinal pigment epithelial cells and/or nerve cells. Specifically, the present invention can include laminin 411 (α4β1γ1), laminin 511 (α5β1γ1), laminin 521 (α5β2γ1), or fragments of these.